Other
Non-Hodgkin Lymphoma by Clinical Course
CI-CAN-00003432Explore in graph →
Hematologic346 active trials12 approved drugs7 evidence items
- NCIt
- C7215
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00003432Explore in graph →
Clinical trials
1,200 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (209)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01193842 | Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas | completed | Phase 1 / Phase 2 | 107 | National Cancer Institute (NCI)NIH | 1 | Nov 21, 2023 | clinicaltrials |
| NCT06136364 | CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study | recruiting | Phase 1 | 9 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Nov 18, 2023 |
| NCT00047060 | Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome | completed | Phase 1 / Phase 2 | 5 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Nov 14, 2023 | clinicaltrials |
| NCT00924170 | Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia | completed | Phase 1 / Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Nov 14, 2023 | clinicaltrials |
| NCT04870853 | Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy | unknown | — | 150 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 14, 2023 | clinicaltrials |
| NCT05138458 | A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL(IMAGINE) | suspended | Phase 1 / Phase 2 | 40 | Myeloid TherapeuticsINDUSTRY | 1 | Nov 13, 2023 | clinicaltrials |
| NCT02763384 | BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma | terminated | Phase 2 | 12 | Washington University School of MedicineOTHER | 1 | Oct 31, 2023 | clinicaltrials |
| NCT03679624 | Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia | terminated | Phase 2 | 1 | Weill Medical College of Cornell UniversityOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT05923502 | (CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL) | not yet recruiting | — | 200 | Ruijin HospitalOTHER | 0 | Oct 23, 2023 | clinicaltrials |
| NCT02916979 | Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG(FluBuATG) | completed | Phase 1 | 20 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Oct 18, 2023 | clinicaltrials |
| NCT04795869 | Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma | withdrawn | Phase 2 | 0 | Northwestern UniversityOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT03697356 | R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's Macroglobulinemia(Ballondor) | unknown | Phase 2 | 54 | Kosin University Gospel HospitalOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT01000753 | Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma | completed | — | 174 | Children's Oncology GroupNETWORK | 4 | Oct 3, 2023 | clinicaltrials |
| NCT01336933 | Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma | completed | Phase 2 | 34 | University of NebraskaOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT00582270 | Prospective Study of Possible Infectious Disease - Associated Antigen Drive in Previously Untreated Indolent Lymphoma | completed | — | 56 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT02661035 | Allo HSCT Using RIC for Hematological Diseases | completed | Phase 2 | 156 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT01336920 | Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma | completed | Phase 1 | 15 | University of NebraskaOTHER | 1 | Sep 15, 2023 | clinicaltrials |
| NCT05979948 | A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's Macroglobulinemia(CZ-WM01) | unknown | Phase 2 | 60 | Shanghai Changzheng HospitalOTHER | 1 | Sep 14, 2023 | clinicaltrials |
| NCT01882803 | A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma(DYNAMO) | completed | Phase 2 | 129 | SecuraBioINDUSTRY | 12 | Sep 7, 2023 | clinicaltrials |
| NCT01044745 | Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer | terminated | Phase 2 | 20 | University of NebraskaOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT02962401 | Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia(RemodelWM3) | completed | Phase 2 | 50 | French Innovative Leukemia OrganisationOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT04409314 | Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy | completed | — | 23 | University of California, San FranciscoOTHER | 1 | Aug 21, 2023 | clinicaltrials |
| NCT03010358 | Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 24 | Alexey Danilov, MDOTHER | 1 | Aug 8, 2023 | clinicaltrials |
| NCT02134782 | Yoga Fatigue Study | terminated | N/A | 125 | The Hospital for Sick ChildrenOTHER | 2 | Aug 1, 2023 | clinicaltrials |
| NCT05020392 | Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma | unknown | Phase 3 | 24 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 25, 2023 | clinicaltrials |
| NCT02847130 | Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology | completed | — | 530 | Children's Oncology GroupNETWORK | 2 | Jul 19, 2023 | clinicaltrials |
| NCT05846750 | Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma | recruiting | Phase 2 | 59 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 19, 2023 | clinicaltrials |
| NCT05941156 | Clinical Study of Anti-CD56-CAR-T in the Treatment of Relapsed/Refractory NK/T Cell Lymphoma /NK Cell Leukemia | unknown | Phase 2 | 20 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Jul 12, 2023 | clinicaltrials |
| NCT05144347 | Study of XL114 in Subjects With Non-Hodgkin's Lymphoma | terminated | Phase 1 | 2 | ExelixisINDUSTRY | 1 | Jul 11, 2023 | clinicaltrials |
| NCT03991884 | Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia | completed | Phase 1 | 24 | University of WashingtonOTHER | 1 | Jul 6, 2023 | clinicaltrials |
| NCT05934097 | FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma | withdrawn | Phase 1 | 0 | Fate TherapeuticsINDUSTRY | 0 | Jul 6, 2023 | clinicaltrials |
| NCT04156828 | Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma | terminated | Phase 1 | 12 | University of WashingtonOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT05576532 | Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia | unknown | Phase 2 | 30 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT03364231 | Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma | completed | Phase 2 | 21 | TG Therapeutics, Inc.INDUSTRY | 1 | Jun 23, 2023 | clinicaltrials |
| NCT01029366 | CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy | completed | Phase 1 | 26 | University of PennsylvaniaOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT02588456 | Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia | terminated | Phase 1 | 5 | University of PennsylvaniaOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT04554511 | Prognostic Nomogram of Extranodal NK/T-cell Lymphoma | unknown | — | 1,000 | Sun Yat-sen UniversityOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT05907447 | A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological Types | unknown | — | 10,000 | Ruijin HospitalOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT03003546 | Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial | completed | Phase 1 | 9 | Mayo ClinicOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT04136756 | NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma | completed | Phase 1 | 30 | Nektar TherapeuticsINDUSTRY | 1 | Jun 15, 2023 | clinicaltrials |
| NCT01378871 | A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma | terminated | Phase 2 | 1 | Amit VermaOTHER | 1 | Jun 9, 2023 | clinicaltrials |
| NCT05380635 | PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma | completed | Phase 2 | 9 | SoligenixINDUSTRY | 1 | Jun 7, 2023 | clinicaltrials |
| NCT05733650 | Expanded Access Program for Epcoritamab | approved for marketing | — | — | GenmabINDUSTRY | 0 | May 25, 2023 | clinicaltrials |
| NCT04121507 | ASTRAL- a Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy | completed | Phase 2 | 60 | GWT-TUD GmbHOTHER | 1 | May 24, 2023 | clinicaltrials |
| NCT01579318 | Phase II Intratumoral IL12 Plasmid Electroporation in Cutaneous Lymphoma(CTCL) | terminated | Phase 2 | 2 | OncoSec Medical IncorporatedINDUSTRY | 1 | May 15, 2023 | clinicaltrials |
| NCT05855460 | Estimation of the Tissue and Serum Levels of Interleukin (IL) -35 in Mycosis Fungoides: a Case Control Study | unknown | — | 20 | Cairo UniversityOTHER | 1 | May 11, 2023 | clinicaltrials |
| NCT02914938 | A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma | terminated | Phase 1 | 97 | MEI Pharma, Inc.INDUSTRY | 2 | May 9, 2023 | clinicaltrials |
| NCT03677128 | Mobile Health Case Management System for Reducing Pediatric Treatment Abandonment | completed | N/A | 75 | Duke UniversityOTHER | 1 | May 9, 2023 | clinicaltrials |
| NCT05840289 | A Study on Fractionated Rituximab to Avoid Lysis Syndrome in Aggressive B-Lymphoma(FRILLY) | unknown | — | 94 | University Hospital, GenevaOTHER | 1 | May 6, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Nov 21, 2023source: clinicaltrials